. . "2" . "http://www.linkos.cz/casopis-klinicka-onkologie/hledani-clanku/skupina/a/zobrazit/ids/4220/" . "Koukalov\u00E1, Renata" . . . "CZ - \u010Cesk\u00E1 republika" . "Castleman Disease: Retrospective single-center study of therapeutic results in 10 patients"@en . "[C74AC506740A]" . "Do retrospektivn\u00ED studie (1998\u20132013) bylo za\u0159azeno 10 pacient\u016F, 6 mu\u017E\u016F a 4 \u017Eeny. Pacienti s unicentrickou formou (3) podstoupili chirurgickou sanaci. Pacienti s multicentrickou formou (7) byli jen sledov\u00E1ni (2), nebo byla provedena exstirpace nejv\u011Bt\u0161\u00ED masy (1), nebo pod\u00E1na syst\u00E9mov\u00E1 l\u00E9\u010Dba (4), kter\u00E1 sest\u00E1vala z n\u00E1sleduj\u00EDc\u00EDch re\u017Eim\u016F: R-CHOP (rituximab, cyklofosfamid, adriamycin, vinkristin, prednison), CTD/CAD/CVD (cyklofosfamid, thalidomid/ adriamycin/bortezomib, dexametazon), d\u00E1le zahrnovala monoterapie tocilizumabem, thalidomidem a lenalidomidem a v jednom p\u0159\u00EDpad\u011B (asociovan\u00FD POEMS syndrom = polyneuropatie, organomegalie, endokrinopatie, monoklon\u00E1ln\u00ED gamapatie, ko\u017En\u00ED zm\u011Bny) byla provedena autologn\u00ED transplantace perifern\u00EDch kmenov\u00FDch bun\u011Bk po p\u0159\u00EDpravn\u00E9m re\u017Eimu s melfalanem. V\u0161ichni pacienti podstoupili v r\u00E1mci sledov\u00E1n\u00ED l\u00E9\u010Debn\u00E9 odpov\u011Bdi vy\u0161et\u0159en\u00ED PET/CT (pozitronov\u00E1 emisn\u00ED tomografie s 18F-fluorodeoxygluk\u00F3zou/v\u00FDpo\u010Detn\u00ED tomografie). Bylo dosa\u017Eeno 50 % remis\u00ED (3 pacienti s unicentrickou formou s remis\u00ED 51, 8 a 9 m\u011Bs\u00EDc\u016F; 2 s multicentrickou formou s remis\u00ED 3 m\u011Bs\u00EDce p\u0159i l\u00E9\u010Db\u011B s thalidomidem a 12 m\u011Bs\u00EDc\u016F po l\u00E9\u010Db\u011B lenalidomidem), ve 40 % p\u0159\u00EDpad\u016F bylo onemocn\u011Bn\u00ED stabiln\u00ED (multicentrick\u00E9 formy, 2 zcela bez l\u00E9\u010Dby, sledov\u00E1n\u00ED 171 a 24 m\u011Bs\u00EDc\u016F; 1 po syst\u00E9mov\u00E9 l\u00E9\u010Db\u011B, sledov\u00E1n\u00ED 23 m\u011Bs\u00EDc\u016F; 1 po dvou exstirpac\u00EDch se stabiln\u00EDm rozsahem lymfadenopatie 15 let, p\u0159i\u010Dem\u017E od prvn\u00ED operace uplynulo 27 let), u jedn\u00E9 pacientky (10 %) do\u0161lo k rychl\u00E9 progresi asociovan\u00E9ho POEMS syndromu s \u00FAmrt\u00EDm (sledov\u00E1na 4 m\u011Bs\u00EDce). Na rozd\u00EDl od unicentrick\u00E9 formy vyl\u00E9\u010Diteln\u00E9 pouhou exciz\u00ED b\u00FDv\u00E1 multicentrick\u00FD typ \u010Dasto refraktern\u00ED k l\u00E9\u010Db\u011B. Z d\u016Fvodu vysok\u00E9 n\u00E1kladov\u00E9 efektivnosti, dobr\u00E9 sn\u00E1\u0161enlivosti a popsan\u00E9ho efektu i v rituximab-rezistentn\u00EDch p\u0159\u00EDpadech up\u0159ednost\u0148ujeme na na\u0161em pracovi\u0161ti p\u0159i l\u00E9\u010Db\u011B multicentrick\u00E9 Castlemanovy choroby imunomodula\u010Dn\u00ED l\u00E9ky (p\u0159edev\u0161\u00EDm thalidomid)."@cs . "The retrospective study (1998\u20132013) included 10 patients, 6 males, 4 females. Patients with unicentric form (3) underwent surgical sanation. Patients with multicentric form (7) were followed-up only (2) or extirpation of the largest mass was carried out (1) or a systemic therapy was administered (4) which comprised the following regimens: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), CTD/CAD/CVD (cyclophosphamide, thalidomide/adriamycin/bortezomib, dexamethasone), further including monotherapies with tocilizumab, thalidomide and lenalidomide and in one case (associated POEMS syndrome, i.e. polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes) autologous stem cell transplantation after melphalan conditioning was performed. During treatment response monitoring, all patients underwent PET/CT examination (fluorodeoxyglucose positron emission tomography/computed tomography). The remission rate was 50% (3 unicentric forms with remission lasting 51, 8 and 9 months, resp.; 2 multicentric forms with remission lasting 3 months during thalidomide therapy and 12 months after lenalidomide therapy), stable disease was observed in 40% of cases (multicentric forms, 2 without any treatment followed-up for 171 and 24 months, resp.; 1 after systemic therapy followed-up for 23 months; 1 after two extirpations with stable lymphadenopathy for 15 years, where the first operation was 27 years ago). In one patient (10%), the associated POEMS syndrome progressed rapidly with fatal consequences (4 months follow-up). Unlike unicentric forms completely curable by excision, multicentric forms are often treatment-refractory. Concerning high cost-effectiveness, good tolerability and documented efficacy also in rituximab-resistant cases, we prefer immunomodulatory drugs (particularly thalidomide) for managing multicentric Castleman disease in our center."@en . "I, P(NT12130), P(NT12215), P(NT13190)" . "RIV/00209805:_____/13:#0000488" . . . . . "Castleman Disease: Retrospective single-center study of therapeutic results in 10 patients"@en . "RIV/00209805:_____/13:#0000488!RIV14-MZ0-00209805" . "2"^^ . "Castlemanova choroba: retrospektivn\u00ED studie l\u00E9\u010Debn\u00FDch v\u00FDsledk\u016F u 10 pacient\u016F z jednoho centra"@cs . . . . . . . . . . . "10"^^ . . "26" . "Castlemanova choroba: retrospektivn\u00ED studie l\u00E9\u010Debn\u00FDch v\u00FDsledk\u016F u 10 pacient\u016F z jednoho centra" . . . "11"^^ . "Canstleman disease; monoclonal antibody; rituximab; tocilizumab; thalidomide; lenalidomide; PET; CT"@en . "Klinick\u00E1 onkologie" . . "Castlemanova choroba: retrospektivn\u00ED studie l\u00E9\u010Debn\u00FDch v\u00FDsledk\u016F u 10 pacient\u016F z jednoho centra"@cs . "Castlemanova choroba: retrospektivn\u00ED studie l\u00E9\u010Debn\u00FDch v\u00FDsledk\u016F u 10 pacient\u016F z jednoho centra" . . . "0862-495X" . "64394" . "\u0158eh\u00E1k, Zden\u011Bk" . . "Do retrospektivn\u00ED studie (1998\u20132013) bylo za\u0159azeno 10 pacient\u016F, 6 mu\u017E\u016F a 4 \u017Eeny. Pacienti s unicentrickou formou (3) podstoupili chirurgickou sanaci. Pacienti s multicentrickou formou (7) byli jen sledov\u00E1ni (2), nebo byla provedena exstirpace nejv\u011Bt\u0161\u00ED masy (1), nebo pod\u00E1na syst\u00E9mov\u00E1 l\u00E9\u010Dba (4), kter\u00E1 sest\u00E1vala z n\u00E1sleduj\u00EDc\u00EDch re\u017Eim\u016F: R-CHOP (rituximab, cyklofosfamid, adriamycin, vinkristin, prednison), CTD/CAD/CVD (cyklofosfamid, thalidomid/ adriamycin/bortezomib, dexametazon), d\u00E1le zahrnovala monoterapie tocilizumabem, thalidomidem a lenalidomidem a v jednom p\u0159\u00EDpad\u011B (asociovan\u00FD POEMS syndrom = polyneuropatie, organomegalie, endokrinopatie, monoklon\u00E1ln\u00ED gamapatie, ko\u017En\u00ED zm\u011Bny) byla provedena autologn\u00ED transplantace perifern\u00EDch kmenov\u00FDch bun\u011Bk po p\u0159\u00EDpravn\u00E9m re\u017Eimu s melfalanem. V\u0161ichni pacienti podstoupili v r\u00E1mci sledov\u00E1n\u00ED l\u00E9\u010Debn\u00E9 odpov\u011Bdi vy\u0161et\u0159en\u00ED PET/CT (pozitronov\u00E1 emisn\u00ED tomografie s 18F-fluorodeoxygluk\u00F3zou/v\u00FDpo\u010Detn\u00ED tomografie). Bylo dosa\u017Eeno 50 % remis\u00ED (3 pacienti s unicentrickou formou s remis\u00ED 51, 8 a 9 m\u011Bs\u00EDc\u016F; 2 s multicentrickou formou s remis\u00ED 3 m\u011Bs\u00EDce p\u0159i l\u00E9\u010Db\u011B s thalidomidem a 12 m\u011Bs\u00EDc\u016F po l\u00E9\u010Db\u011B lenalidomidem), ve 40 % p\u0159\u00EDpad\u016F bylo onemocn\u011Bn\u00ED stabiln\u00ED (multicentrick\u00E9 formy, 2 zcela bez l\u00E9\u010Dby, sledov\u00E1n\u00ED 171 a 24 m\u011Bs\u00EDc\u016F; 1 po syst\u00E9mov\u00E9 l\u00E9\u010Db\u011B, sledov\u00E1n\u00ED 23 m\u011Bs\u00EDc\u016F; 1 po dvou exstirpac\u00EDch se stabiln\u00EDm rozsahem lymfadenopatie 15 let, p\u0159i\u010Dem\u017E od prvn\u00ED operace uplynulo 27 let), u jedn\u00E9 pacientky (10 %) do\u0161lo k rychl\u00E9 progresi asociovan\u00E9ho POEMS syndromu s \u00FAmrt\u00EDm (sledov\u00E1na 4 m\u011Bs\u00EDce). Na rozd\u00EDl od unicentrick\u00E9 formy vyl\u00E9\u010Diteln\u00E9 pouhou exciz\u00ED b\u00FDv\u00E1 multicentrick\u00FD typ \u010Dasto refraktern\u00ED k l\u00E9\u010Db\u011B. Z d\u016Fvodu vysok\u00E9 n\u00E1kladov\u00E9 efektivnosti, dobr\u00E9 sn\u00E1\u0161enlivosti a popsan\u00E9ho efektu i v rituximab-rezistentn\u00EDch p\u0159\u00EDpadech up\u0159ednost\u0148ujeme na na\u0161em pracovi\u0161ti p\u0159i l\u00E9\u010Db\u011B multicentrick\u00E9 Castlemanovy choroby imunomodula\u010Dn\u00ED l\u00E9ky (p\u0159edev\u0161\u00EDm thalidomid)." .